Kinnate Biopharma Inc.

Kinnate Biopharma Inc.

KNTE

KNTEKinnate Biopharma Inc. US flag

NASDAQ Global Select

2.65

USD

-0.01

- -

124.99MMarket Cap

Kinnate Biopharma Inc.

KNTE

(NASDAQ Global Select)

Recent

price

2.65

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Impel Pharmaceuticals Inc. (IMPL)
Panbela Therapeutics, Inc. (PBLA)
Janux Therapeutics, Inc. (JANX)
Dyne Therapeutics, Inc. (DYN)
MedMira Inc. (MIR.V)
iBio, Inc. (IBIO)
Business: Kinnate Biopharma Inc. Kinnate Biopharma Inc. (Nasdaq: KNTE), founded in 2018 and headquartered in San Diego, California, with additional operations in San Francisco, California, operates as a clinical-stage precision oncology company that discovers, designs, and develops small molecule kinase inhibitors targeting validated oncogenic drivers of cancer for which approved therapies are limited or ineffective. The company focuses on patient populations with genetically driven solid tumors lacking targeted treatments, those exhibiting intrinsic resistance to existing therapies, or those developing acquired resistance; its proprietary pipeline leverages structure-based drug design emphasizing high selectivity, optimized pharmaceutical properties, broad genetic alteration coverage, and brain penetration capabilities. Core product candidates include the investigational pan-RAF inhibitor exarafenib for BRAF- and NRAS-driven advanced adult solid tumors such as melanoma and non-small cell lung cancer; the investigational FGFR inhibitor KIN-3248 targeting FGFR2/3 alterations in cancers including cholangiocarcinoma; a brain-penetrant MEK inhibitor KIN-7136 designed for combination with exarafenib in RAF inhibitor-pretreated patients; a highly selective c-MET inhibitor KIN-8741 addressing overexpression and resistance mutations in non-small cell lung cancer and other solid tumors; and an early-stage brain-penetrant CDK4-selective program. In recent major developments, Kinnate sold global rights to exarafenib and related pan-RAF assets to Pierre Fabre Laboratories in March 2024 pursuant to an asset purchase agreement amid its strategic review. XOMA Royalty Corporation XOMA Royalty Corporation acquired Kinnate in April 2024 through a tender offer and merger, adding approximately $9.5 million in net cash to its balance sheet while gaining control of the remaining pipeline programs. In April 2025, XOMA Royalty sold all five acquired Kinnate pipeline assets—encompassing the FGFR, MEK, c-MET, and CDK4 programs—for upfront and milestone payments up to $270 million plus low single- to mid-teen royalties on future commercial sales, with 85% of pre-2029 proceeds allocated to legacy Kinnate shareholders via contingent value rights. These transactions followed a 2023 strategic restructuring involving 70% workforce layoffs and discontinuation of three programs, alongside addition of the MEK and c-MET candidates earlier that year. Kinnate primarily serves global oncology markets, concentrating on precision medicine for advanced solid tumors.

Company News